Amino Acid-dependent Control of p70s6k
INVOLVEMENT OF tRNA AMINOACYLATION IN THE REGULATION*

Yasuhiko IiboshiDagger , Philip J. PapstDagger , Hideki KawasomeDagger , Hajime Hosoi§, Robert T. Abraham, Peter J. Houghton§, and Naohiro TeradaDagger parallel

From the Dagger  Department of Pediatrics, Division of Basic Sciences, National Jewish Medical and Research Center, Denver, Colorado 80206, the § Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, and the  Mayo Clinic and Foundation, Department of Immunology and Pharmacology, Rochester, Minnesota 55905

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In human T-lymphoblastoid cells, downstream signaling events of mammalian target of rapamycin (mTOR), including the activity of p70s6k and phosphorylation of eukaryotic initiation factor 4E-binding protein 1, were dependent on amino acid concentration in the culture media, whereas other growth-related protein kinases were not. Amino acid-induced p70s6k activation was completely inhibited by rapamycin but only partially inhibited by wortmannin. Moreover, amino acid concentration similarly affected the p70s6k activity, which was dependent on a rapamycin-resistant mutant (S2035I) of mTOR. These data indicate that mTOR is required for amino acid-dependent activation of p70s6k. The mechanism by which amino acids regulate p70s6k activity was further explored: 1) amino acid alcohols, which inhibit aminoacylation of tRNA by their competitive binding to tRNA synthetases, suppressed p70s6k activity; 2) suppression of p70s6k by amino acid depletion was blocked by cycloheximide or puromycin, which inhibit utilization of aminoacylated tRNA in cells; and 3) in cells having a temperature-sensitive mutant of histidyl tRNA synthetase, p70s6k was suppressed by a transition of cells to a nonpermissible temperature, which was partially restored by addition of high concentrations of histidine. These results indicate that suppression of tRNA aminoacylation is able to inhibit p70s6k activity. Deacylated tRNA may be a factor negatively regulating p70s6k.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The p70 S6 kinase (p70s6k)1 is a serine/threonine kinase that is ubiquitously activated at the G0/G1 transition of the cell cycle in mammalian cells (1-3). This protein kinase phosphorylates 40 S ribosomal S6 protein at five serine residues near the carboxyl terminus in vitro (4). Studies using targeted disruption of the p70s6k gene (5) and using transfection of a dominant negative or a rapamycin-resistant mutant of p70s6k (6, 7) have shown that p70s6k mediates S6 phosphorylation in vivo. S6 phosphorylation has been proposed to be a factor regulating initiation of mRNA translation (see review in Ref. 8), and the studies described above (5, 6) concluded that the role of p70s6k in cell proliferation resides in specific regulation of translation of mRNAs encoding ribosomal proteins. Thus, p70s6k activity is considered to be a factor required for up-regulation of ribosomal biogenesis, which facilitates G1 progression during the cell cycle (9).

In regards to the activation of p70s6k, it appears there are at least two upstream regulatory pathways; one is through phosphatidyl inositol-3 kinase (PI3K) and the other is through mammalian target of rapamycin (mTOR; also termed FRAP and RAFT). Many growth factors, such as platelet-derived growth factor and epidermal growth factor, activate PI3K through their binding to specific receptors, and previous studies using chemical inhibitors of PI3K, mutant platelet-derived growth factor receptors, and mutant PI3Ks, all indicated that PI3K is involved in the activation of p70s6k by growth factors (10-13). Indeed, it has been demonstrated recently that PDK1, a downstream kinase of PI3K, phosphorylates p70s6k at Thr229 and activates the kinase (14, 15).

The involvement of mTOR in the regulation of p70s6k has been initially demonstrated by studies using the immunosuppressive drug rapamycin (see reviews in Refs. 16 and 17). Rapamycin associates with a cellular protein FKBP12 in cells, and the rapamycin-FKBP12 complex then binds to mTOR. It has also been demonstrated that mTOR is required for the inhibitory action of rapamycin on p70s6k (18). Moreover, mTOR has an intrinsic protein serine/threonine kinase activity and regulates the activity and phosphorylation of p70s6k in vivo in a manner that is dependent on the kinase activity of mTOR (18). Although initial reports concluded that mTOR did not directly phosphorylate p70s6k, it has been demonstrated that mTOR phosphorylates p70s6k at Thr389 in vitro (19). In addition to p70s6k, mTOR regulates another translation regulatory molecule, eIF-4E-binding protein 1 (4E-BP1) (20-23), independent of p70s6k activity (5, 6). mTOR is demonstrated to phosphorylate the translation repressor protein 4E-BP1 at its serine and threonine residues (24). The hypophosphorylated species of 4E-BP1 binds tightly to eIF-4E (an N7-methylguanosine cap-binding subunit of eIF-4F complex) and prevents eIF-4E from associating with eIF-4G (a scaffolding protein in eIF-4F complex). The phosphorylation of 4E-BP1 by mTOR is thought to release eIF-4E and facilitate translational initiation of capped mRNA (21). Thus, mTOR regulates 1) ribosomal protein synthesis at the level of mRNA translation through p70s6k activity, and 2) overall protein synthesis by controlling translational initiation of capped mRNA through 4E-BP1.

In contrast to the PI3K pathway, which is activated by various growth factors, it was unclear what factor physiologically regulated mTOR. A study on proteolytic responses to amino acid deprivation demonstrated that ribosomal S6 phosphorylation was induced by supplementation of amino acids (25), suggesting that amino acid concentration in culture media may be a regulatory factor for p70s6k. Indeed, Fox et al. (26) demonstrated that amino acids stimulate phosphorylation of p70s6k in rat adipocytes. More recently, Hara et al. (27) have reported that amino acid concentration regulates p70s6k activity and phosphorylation of 4E-BP1 in Chinese hamster ovary cells. The study demonstrated that a rapamycin-resistant mutant (p70Delta 2-46/Delta CT104) of p70s6k was resistant to amino acid deprivation, indicating that amino acid sufficiency and mTOR both signal to p70s6k through a common effector, which could be mTOR itself or an mTOR-controlled downstream element. In this study, we further explored the mechanism by which amino acid concentration regulates p70s6k.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cells and Reagents-- Human T-lymphoblastoid Jurkat cells were obtained from ATCC. Human alveolar rhabdomyosarcoma Rh30 cells were established from the bone marrow of a patient with metastatic tumor (28). Rh30 cells constitutively expressing wild type mTOR (WT-mTOR) or a rapamycin-resistant mTOR (S2035I) were obtained by transfection of cells with pcDNA3-AU1mTORwt or pcDNA3-AU1mTORSI. BHK21 cells and their temperature-sensitive mutant temperature-sensitive (ts) BN250 were obtained from RIKEN cell bank (Tsukuba, Japan). Rapamycin and wortmannin were obtained from Calbiochem (San Diego, CA), and stored in ethanol (1 mg/ml) and dimethyl sulfoxide (10 mM), respectively. Cycloheximide (Sigma) was dissolved in ethanol and stored as a 10 mg/ml stock solution. Puromycin (Sigma) was stored in distilled water (2 mg/ml). Amino acid alcohols (Sigma) L-leucinol, L-phenylalaninol, L-alaninol, L-histidinol, L-tyrosinol, L-methioninol, and D-leucinol were stored in distilled water (5 M). Methyl 2-aminoisobutyric acid (MeAIB) and 2-amino-2-norbornane-carboxylic acid were obtained from Sigma and stored in distilled water at 200 and 100 mM, respectively.

Cell Culture-- Jurkat cells and Rh30 cells were maintained in RPMI 1640 medium (Life Technologies, Inc.) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) (HyClone, Logan, UT), 100 units/ml penicillin, and 100 µg/ml streptomycin (Life Technologies). For amino acid deprivation, exponentially growing cells were washed twice with amino acid-free RPMI 1640 medium (RPMI 1640 select-amine kit, catalog no. 17402, Life Technologies) and resuspended at 5 × 105 cells/ml in the same amino acid-free RPMI 1640 medium supplemented with 10% dialyzed FCS (catalog no. 26300, Life Technologies) for the indicated times at 37 °C in a 5%-CO2 incubator. In some experiments, individual amino acids were deprived instead of total amino acid deprivation. For amino acid supplementation, cells (5 × 105 cells/ml) were incubated in the amino acid-free RPMI 1640 medium supplemented with 10% dialyzed FCS for 3-16 h. The same volume of RPMI 1640 medium containing 2× concentrations of amino acids +10% dialyzed FCS were added to the culture, and cells were incubated for the indicated times. The concentrations (in µM) of amino acids (1×) in RPMI 1640 (Life Technologies) were as follows: Gln, 2050; Asn, 380; His, 100; Trp 24; Pro, 170; Cyst, 410; Gly, 130; Val, 170; Leu, 380; Ile, 380; Ser, 290; Thr, 170; Phe, 90; Tyr, 110; Met, 100; Glu, 140; Asp 150; Arg, 1150; and Lys, 220. BHK21 and tsBN250 cells were maintained in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% (v/v) heat-inactivated FCS (HyClone) at 33 °C in a 5%-CO2 incubator. For transition of cells to nonpermissible temperature, culture plates were transferred to a 5%-CO2 incubator at 39 °C.

Kinase Assay-- Cells (2 × 106) were harvested, and the activities of the kinases were measured as we described previously (3). Briefly, cells were lysed in a buffer containing 10 mM potassium phosphate, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM beta -glycerophosphate, 1 mM Na3VO4, 2 mM dithiothreitol, 40 µg/ml phenylmethylsulfonyl fluoride, and 0.1% Nonidet P-40. The protein kinases in 250 µg of total cellular proteins were immunoprecipitated using specific antibodies: for p70s6k, a rabbit polyclonal antibody raised against the carboxyl-terminal 18 amino acids of p70s6k (sc-230, Santa Cruz Biotechnology, Santa Cruz, CA); for Akt, a goat polyclonal antibody against an epitope corresponding to amino acids 461-480 of human Akt1 (sc-1618, Santa Cruz Biotechnology); for p90rsk, a rabbit polyclonal antibody raised against an epitope 682-724 of mouse Rsk1 (06-185, Upstate Biotechnology, Lake Placid, NY); and for Cdk2, a rabbit polyclonal antibody raised against an epitope 283-298 of human Cdk2 (sc-163, Santa Cruz Biotechnology). The kinase activity was measured by incorporation of 32P into specific substrate peptides (for p70s6k and p90rsk, an S6 peptide, RRRLSSLRA; for Akt, a Gsk3 peptide, GRPRTSSFAEG; for Cdk2, a histone H1 peptide, AVAAKKSPKKAKKPA).

Immunoblot-- Cells (5 × 106) were washed with phosphate-buffered saline and lysed at 4 °C with 25 mM Tris-HCl, pH 7.4, 50 mM NaCl, 0.5% sodium deoxycholate, 2% Nonidet P-40, 0.2% SDS, 1 µM phenylmethylsulfonyl fluoride, 50 µg/ml aprotinin, 50 µM leupeptin. Lysates were resolved by SDS 7.5% (for p70s6k) or 15% (for 4E-BP1) polyacrylamide gels and transferred to nitrocellulose filters. After blocking of the filters with a solution containing 1% bovine serum albumin, the filters were incubated with primary antibodies. The antibodies used for p70s6k are the same as described above. For 4E-BP1, a rabbit polyclonal antibody raised against a recombinant His-tagged rat PHAS1 (4E-BP1) was used (24). Specific reactive proteins were detected by the ECL method, employing a donkey anti-rabbit Ig antibody linked to horseradish peroxidase (Amersham Pharmacia Biotech).

Amino Acid Uptake-- Cells (2 × 106) were harvested, centrifuged at 1500 rpm for 5 min, and resuspended in 100 µl of a buffer containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 5 mM D-glucose, 25 mM HEPES (pH 7.5), 25 mM Tris (pH 7.5). The cell suspension was loaded on 100 µl of a buffer containing 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 5 mM D-glucose, 25 mM HEPES (pH 7.5), 25 mM Tris (pH 7.5), 50 µM nonradioactive His, and 1 µl (1 µCi) of [3H]His (1 mCi/ml) (Amersham Pharmacia Biotech) with or without 10 mM of L-histidinol, layered on 300 µl of silicone oil/paraffin oil (92:8) in microcentrifuge tubes (29). After the indicated time (30 s, 2 min, 5 min, 30 min, or 60 min), cells were centrifuged for 2 min at 14,000 rpm, and water phase was discarded. After washing surface of oil twice with 750 µl of phosphate-buffered saline, oil phases were discarded also. Cell pellets were then lysed in 50 µl of saline with 2% Triton X-100. Radioactivity of the total lysates was measured using a liquid scintillation counter.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Amino Acid Deprivation Inactivated and Supplementation Activated p70s6k but Not Other Protein Serine/Threonine Kinases-- The human T-lymphoblastoid cell line, Jurkat cells, were transferred to an amino acid-free medium supplemented with 10% dialyzed FCS and incubated for the indicated times (amino acid deprivation). In addition, after culturing cells in the amino acid-free medium with 10% dialyzed FCS for 16 h, cells were transferred to the regular RPMI 1640 medium containing amino acids with 10% dialyzed FCS and incubated at the indicated times (amino acid supplementation). Initially, the activity of p70s6k was measured in the system, as well as the activities of other growth-related serine/threonine kinases, Akt, p90rsk, and Cdk2 (Fig. 1). p70s6k activity decreased within 15 min after deprivation of amino acids and became undetectable within 30 min; levels remained undetectable throughout the time course. Additionally, supplementation of amino acids increased p70s6k activity within 15 min, and the activity reached a plateau level within 60 min. In contrast, the activity of Akt, which is a downstream kinase of PI3K (13), was not inhibited by amino acid deprivation, nor did it increase following amino acid supplementation. p90rsk is a downstream kinase of extracellular signal-regulated kinases and has the highest homology with p70s6k in the catalytic domains (30). In contrast to p70s6k, the activity of p90rsk transiently increased by transferring cells to an amino acid-free medium, and then decreased gradually. However, p90rsk remained partially active throughout the time course of the experiments. Additionally, amino acid supplementation transiently decreased p90rsk activity, but overall it did not dramatically alter kinase activity for 360 min. Cdk2 is active especially at the late G1 and S phases of the cell cycle. Cdk2 activity was partially decreased by both amino acid deprivation and by supplementation within 30 min, but the kinase remained partially active throughout the time course.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of amino acid deprivation and supplementation on the activities of p70s6k, Akt, p90rsk, and Cdk2. A, amino acid deprivation. Exponentially growing Jurkat cells were washed twice with amino acid-free RPMI 1640 medium and resuspended at 5 × 105 cells/ml in the same amino acid-free medium supplemented with 10% dialyzed FCS for the indicated times at 37 °C in a CO2 incubator. B, amino acid supplementation. Jurkat cells (5 × 105 cells/ml) were incubated in the amino acid-free medium with 10% dialyzed FCS for 16 h. The same volume of RPMI 1640 medium containing 2× concentrations of amino acids + 10% dialyzed FCS were added into the culture, and cells were incubated for the indicated times. Cells (2 × 106) were harvested, and the specific activity of immunoprecipitated p70s6k, Akt1, p90rsk, or Cdk2 was measured by incorporation of 32P into specific substrate peptides as described under "Experimental Procedures." Error bars here and in figures below represent S.D. of the data. Results show one representative experiment out of three.

Amino Acid Supplementation Increased Phosphorylation of p70s6k and 4E-BP1-- The hyperphosphorylated species of p70s6k, which correspond to the active form of the kinase, is determined as a band(s) with a lower mobility in immunoblots (9). On the other hand, the hypophosphorylated p70s6k, which corresponds to the inactive form of the kinase, is determined as a band with the highest mobility. Cells treated with an amino acid-starved medium demonstrated only the hypophosphorylated species of p70s6k, and supplementation of amino acids increased the hyperphosphorylated species of p70s6k within 5-15 min (Fig. 2). In contrast to p70s6k, amino acid deprivation/supplementation essentially did not alter the phosphorylation status of p90rsk, similarly evaluated by a mobility shift in an immunoblot analysis (data not shown).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of amino acid supplementation on the phosphorylation of p70s6k and 4E-BP1. Jurkat cells (5 × 105 cells/ml) were incubated in the amino acid-free medium with 10% dialyzed FCS for 16 h. The same volume of RPMI 1640 medium containing 2× concentrations of amino acids + 10% dialyzed FCS were added into the culture, and cells were incubated for the indicated times. The protein extracts from cells were separated in 7.5% (for p70s6k) or 15% (for 4E-BP1)-SDS-polyacrylamide gel and transferred to nitrocellulose filters. The specific proteins were detected by immunoblotting using the ECL method as described under "Experimental Procedures." Results show one representative experiment out of three.

The phosphorylation status of 4E-BP1, another downstream event of mTOR, was also examined by a gel mobility shift in an immunoblot assay (20-23). Cells treated with an amino acid-starved medium demonstrated bands with higher mobilities, corresponding to the hypophosphorylated species of 4E-BP1. Amino acid supplementation induced bands with lower mobilities, which correspond to hyperphosphorylated 4E-BP1, within 15 min. These hyperphosphorylated bands became more predominant within 1-3 h. Additionally, hyperphosphorylated species of p70s6k and 4E-BP1 were eliminated by amino acid deprivation within 5-15 min and 30 min, respectively (data not shown).

Rapamycin, but Not Wortmannin, Inhibited Amino Acid-induced p70s6k Activation-- Because amino acid concentrations affected p70s6k without affecting Akt activity, it does not seem that amino acids regulate p70s6k through PI3K. Furthermore, similar effects of amino acids on p70s6k and 4E-BP1 suggested that mTOR, or an unidentified factor that mediates mTOR signals to both p70s6k and 4E-BP1, is involved in amino acid-induced activation of p70s6k. In order to further investigate these observations, the effects of wortmannin and rapamycin on amino acid-induced p70s6k activation were examined. Jurkat cells were treated in an amino acid-free medium for 16 h and then supplemented with total amino acids or none for 1 h in the presence or absence of specific inhibitors of PI3K and mTOR, wortmannin (100 nM) and rapamycin (10 ng/ml), respectively. As shown in Fig. 3, p70s6k activation induced by amino acid addition was inhibited by rapamycin. In contrast, wortmannin at the concentration that is known to inhibit PI3K activity over 95% inhibited p70s6k only by ~25%. In contrast, Akt, which was already active in the cell culture regardless of amino acid concentrations, was inhibited by wortmannin by about 60%. Similar to the p70s6k activity, 4E-BP1 phosphorylation induced by amino acid addition was inhibited by rapamycin but not by wortmannin (data not shown).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   Rapamycin but not wortmannin inhibits amino acid-induced p70s6k activation. Jurkat cells (5 × 105 cells/ml) were incubated in amino acid-free medium with 10% dialyzed FCS for 16 h. Then, the same volume of either a medium containing 2× concentrations of amino acids + 10% dialyzed FCS (AA(+)) or amino acid-free medium + 10% dialyzed FCS (AA(-)) were added into the culture for 1 h. Rapamycin (RAP) (10 ng/ml) or wortmannin (WOR) (100 nM) was added to the culture 15 min prior to the addition of AA(+) medium or AA(-) medium. Cells were harvested, and the activities of p70s6k and Akt were measured as described above. Results show one representative experiment out of three.

Rapid activation of p70s6k (within 15 min) after re-addition of total amino acids suggested that this may be independent of newly synthesized proteins. In order to confirm this, cycloheximide was added to the culture before addition of total amino acids. Cycloheximide (100 µM), which inhibits protein synthesis over 95%, did not inhibit amino acid-induced p70s6k activation (data not shown). These data indicate that amino acids activate p70s6k independent of newly synthesized proteins.

Amino Acid Supplementation Induced p70s6k Activation in the Presence of Rapamycin in Cells Expressing a Rapamycin-resistant Mutant of mTOR-- In order to further investigate mechanisms by which amino acids regulate the mTOR pathway, we utilized cells constitutively expressing a rapamycin-resistant mTOR. Human rhabdomyosarcoma Rh30 cells constitutively expressing either WT-mTOR or a rapamycin-resistant mutant (S2035I-mTOR) were obtained by co-transfection of the mTOR expression vectors and a neo-resistant gene expression vector, followed by G418 selection as described previously (31). Parental Rh30 cells, WT-mTOR Rh30 cells, or S2035I-mTOR Rh30 cells were first incubated for 3 h in an amino acid-deprived medium. Rapamycin (10 ng/ml) was then added to the culture. Thirty min after addition of rapamycin, total amino acids were added, and cells were incubated for the indicated times. As shown in Fig. 4, amino acid supplementation was not able to induce p70s6k in the presence of rapamycin in parental Rh30 cells or WT-mTOR Rh30 cells, as shown in Jurkat cells above. In contrast, amino acids did induce p70s6k in the presence of rapamycin in S2035I-mTOR Rh30 cells.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Amino acid sensitivity of p70s6k in the presence of rapamycin in cells constitutively expressing S2035I-mTOR. Exponentially growing Rh30 cells (parent, WT-mTOR, or S2035I-mTOR) were first treated with amino acid-free medium for 3 h. Rapamycin (10 ng/ml) was then added to the culture. After 30 min, the same volume of RPMI 1640 medium containing 2× concentrations of amino acids + 10% dialyzed FCS were added into the culture (time 0). Cells were harvested at the indicated times, and p70s6k activity was measured as described above. WT-mTOR and S2035I-mTOR are Rh30 cells constitutively expressing wild type mTOR and S2035I mutant of mTOR, respectively. Results show one representative experiment out of two.

Effects of Selective Inhibitors for Amino Acid Transport Systems on Amino Acid-induced p70s6k Activation-- The mechanism by which amino acids regulate p70s6k activity was further explored. Fox et al. (26) reported that supplementation of a set of neutral amino acids, which were preferentially transported by system L transporter, was able to induce p70s6k phosphorylation. In contrast, another set of neutral amino acids preferentially transported by system A or ASC, or a set of charged amino acids, was less effective. A potential explanation for these results is that a specific amino acid transporter, such as system L, is linked to activation of p70s6k. In order to investigate this possibility, we examined the effects of specific inhibitors of various amino acid transporter systems on amino acid-induced p70s6k activation. There are three major amino acid transporter systems known for uptake of neutral amino acids; system A, system L, and system ASC. It is reported that over 90% of neutral amino acids are transported through these three systems in mammalian cells (32). Each of the three systems has a model substrate that has a high affinity to the system. MeAIB has a high affinity to system A and competitively inhibits transport of other amino acids through the system. In contrast, MeAIB does not significantly affect transport of amino acids through other transporters, including system L and system ASC. Similarly, 2-amino-2-norbornane-carboxylic acid and cysteine can competitively inhibit amino acids-transport through system L and system ASC, respectively. Jurkat cells were initially incubated with amino acid-deprived medium for 16 h, and then <FR><NU>1</NU><DE>16</DE></FR> concentrations of total amino acids contained in regular RPMI 1640 medium were added to the culture in the presence or absence of these competitive model substrates (10 mM). This concentration of total amino acids was able to induce approximately one-half the activity of p70s6k when compared with addition of 1× total amino acids of RPMI 1640 medium. As shown in Fig. 5, all of the model substrates partially inhibit p70s6k activation induced by amino acid supplementation. This is inconsistent with the idea that a specific neutral transporter is linked to p70s6k activation. If amino acid transporters are signaling mediators that sense extracellular amino acid concentration and subsequently transduce signals to p70s6k, then the data suggest that all three systems should link to p70s6k activation. Alternatively, the data may be explained by altered intracellular amino acid concentration.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of selective inhibitors for neutral amino acid-transport systems on amino acid-induced p70s6k activation. Jurkat cells (5 × 105 cells/ml) were incubated in amino acid-free medium with 10% dialyzed FCS for 16 h. <FR><NU>1</NU><DE>16</DE></FR> concentrations of total amino acids contained in RPMI 1640 were added to the culture in the presence of a vehicle (distilled water (control)) or 10 mM of 2-amino-2-norbornane-carboxylic acid, MeAIB, or Cys for 1 h. Cells were harvested, and the activity of p70s6k was measured as described above. Results show one representative experiment out of three.

Amino Acid Alcohols Inhibit p70s6k Activity-- The mechanism by which the cell recognizes the lack of an amino acid seems reasonably well understood in bacteria and yeast, and basically it is through increased concentration of intracellular deacylated tRNA or, in some cases, through reduced availability of aminoacylated tRNA (see under "Discussion"). In order to investigate the involvement of the tRNA aminoacylation in the regulation of p70s6k in mammalian cells, we initially utilized amino acid alcohols. The alcohol derivatives of amino acids inhibit their corresponding tRNA synthetases and thus prevent aminoacyl-tRNA formation (33, 34). For example, L-histidinol inhibits L-His binding to tRNAHis synthetase and thereby increases deacylated tRNAHis. Various amino acid alcohols were added to exponentially growing Jurkat cells. As shown in Fig. 6A, addition of 2 mM of either leucinol, phenylalaninol, alaninol, histidinol, tyrosinol, or methioninol (all L-type) inhibited p70s6k activity to various extents in 30 min. Addition of D-leucinol, in contrast, did not inhibit p70s6k activity. It should also be noted that addition of D-amino acids, including D-Leu and D-Gln, did not increase p70s6k activity in total amino acid-starved cells, whereas addition of L-Leu or L-Gln did increase p70s6k activity partially (data not shown). The dose response, time effect, and specificity of amino acid alcohols on p70s6k was examined using histidinol, one of the most effective amino acid alcohols in the inhibition of p70s6k. Fig. 6B demonstrates the dose response of histidinol in the inhibition of p70s6k. Histidinol (10 mM) inhibited p70s6k activity within 30 min and activity remained low for 24 h (Fig. 6C). The time course was compatible with that of p70s6k activity upon total amino acid deprivation (Fig. 1A). For comparison, the time course of His deprivation on p70s6k is shown in Fig. 6C as well. His deprivation decreased p70s6k activity to an extent similar to histidinol within 30 min, but there was a rebound of the kinase activity within 1-6 h after deprivation of the amino acid. This transient rebound was also observed when lower concentrations of histidinol (0.5 or 2 mM) were added to the culture. The effects of histidinol on p70s6k activity was considered to be specific and not due to its toxic effects on cells, because it did not affect p90rsk, Akt, or cdk2 within 6 h (Fig. 6D). Additionally, we confirmed that the effect of histidinol was not mediated through inhibition of His transport (Fig. 6E). Uptake of histidine within 60 min after addition of radiolabeled His was not affected by the presence of 10 mM histidinol. These data suggest that blockade of tRNA aminoacylation may inhibit p70s6k.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of amino acid alcohols. A, effects of various amino acid alcohols. Exponentially growing Jurkat cells were incubated with 2 mM of amino acid alcohols for 30 min. Cells were harvested and the activity of p70s6k was measured as described above. Amino acid alcohols used here were L-leucinol, L-phenylalaninol, L-alaninol, L-histidinol, L-tyrosinol, L-methioninol, and D-leucinol. Results here and below show one representative experiment out of three to five. B, dose effect of L-histidinol. Exponentially growing Jurkat cells were incubated with 0-10 mM of L-histidinol for 30 min. Cells were harvested, and the activity of p70s6k was measured as described above. C, time course of L-histidinol. Exponentially growing Jurkat cells were incubated with 10 mM of L-histidinol for 0-24 h. Alternatively cells were transferred to histidine-free RPMI 1640 medium supplemented with 10% dialyzed FCS (His deprivation). Cells were harvested at the indicated times, and the activity of p70s6k was measured as described above. D, effects of L-histidinol on other growth-related kinases. Exponentially growing Jurkat cells were incubated with 10 mM of L-histidinol for 0-6 h. Cells were harvested, and the activities of p70s6k, Akt, p90rsk, and Cdk2 were measured as described above. The data are shown by percentage of activity compared to the activity of each kinase in cells before treatment of histidinol. E, effects of L-histidinol on His uptake into cells. Exponentially growing Jurkat cells were harvested, and [3H]His uptake (~50 µM of total His) into cells (within 0.5-60 min) was measured in the presence or absence of 10 mM L-histidinol as described under "Experimental Procedures."

Effects of Inhibitors of Peptide Elongation-- Cycloheximide is an inhibitor of peptidyl transferase, and puromycin interferes peptide elongation by accepting the nascent peptide chain from the peptidyl tRNA molecule on the ribosome (35). Because these drugs block the utilization of aminoacylated tRNA by interfering with peptide elongation, their action is expected to cause a shift in the aminoacylation equilibrium (36). The ratio of deacylated tRNAs decreases by addition of cycloheximide or puromycin in regular cell culture conditions (37). Additionally, the increase in deacylated tRNAs is thought to be minimized by the drugs when amino acid supply is limited (38). Exponentially growing Jurkat cells were transferred to amino acid-depleted medium in the presence or absence of cycloheximide (1 µM) or puromycin (100 µg/ml) (Fig. 7). A decrease in amino acid concentration to 1/4 did not change p70s6k activity significantly, and a decrease to <FR><NU>1</NU><DE>16</DE></FR> reduced p70s6k activity by about one-half in 1 h. Both cycloheximide and puromycin enhanced p70s6k activity when cells were transferred to the medium containing 1/4 and <FR><NU>1</NU><DE>16</DE></FR> concentrations of amino acids. Inhibition of p70s6k activity by decrease in amino acid concentration to <FR><NU>1</NU><DE>16</DE></FR> was completely blocked by the drugs. These data support the idea that increase in deacylated tRNA or decrease in aminoacylated tRNA is a factor suppressing p70s6k.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of cycloheximide or puromycin on amino acid depletion-induced p70s6k suppression. Exponentially growing Jurkat cells were transferred to RPMI 1640 medium containing 1/4× or <FR><NU>1</NU><DE>16</DE></FR>× concentrations of amino acids + 10% dialyzed FCS, in the presence of cycloheximide (1 µM) or puromycin (100 µg/ml), or in the absence of the drugs (control) for 1 h. Cells were harvested, and the activity of p70s6k was measured as described above. The p70s6k activity of cells transferred to the medium containing a 1× concentration of amino acids was 13,894 cpm. The data are shown by percentage of activity compared to this value. Results show one representative experiment out of two.

Study Using a Temperature-sensitive Mutant of tRNA Synthetase-- There have been several reports describing temperature-sensitive mutants of mammalian cells that contain mutations in the tRNA synthetases. Here, we utilized tsBN250 cells that were derived from a golden hamster kidney BHK21 cell line (39). tsBN250 has a point mutation at the histidyl-tRNA synthetase gene, which likely alters normal protein folding (39). The activity of the mutated tRNA synthetase is very low or undetectable and cannot support cell growth unless excess amounts of His are supplemented at nonpermissible temperature (39 °C) (39). Using these lines, we examined the correlation of tRNA synthetase activity in the cells with p70s6k activity. BHK21 and tsBN250 cells were maintained at permissible 33 °C. Cells were transferred to 39 °C incubator and cell numbers and p70s6k activity were monitored. As shown in Fig. 8A, growth of tsBN250 cells was arrested in nonpermissible temperature, and it was partially recovered by addition of high concentrations of His, but not of Lys, to the culture medium. Transfer to nonpermissible temperature decreased p70s6k in tsBN250 cells within 30 min but not in parental BHK21 cells (Fig. 8B). There was a rebound of the kinase activity in tSBN250 cells within 2-6 h after transferring cells to 39 °C as seen in a His deprivation experiment (Fig. 6C). The inhibition of p70s6k in tsBN250 cells was partially recovered by addition of high concentrations of His, the corresponding amino acid for the mutated tRNA synthetase, but not by Lys (Fig. 8C). In contrast to p70s6k, activity of p90rsk in tsBN250 cells was not altered by the changing temperature or by addition of extra amino acids. These data suggest that inhibition of tRNAHis aminoacylation led to the suppression of p70s6k activity.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 8.   Study using a temperature-sensitive mutant of tRNA synthetase. A golden hamster kidney BHK21 cell line and its temperature-sensitive mutant tsBN250 cells, which have a point mutation at the histidyl-tRNA synthetase gene, were maintained at 33 °C. A, cell growth. BHK21 and tsBN250 cells were transferred to a 39 °C incubator with or without supplementation of high concentrations of His (2 mM) or Lys (10 mM). Cell numbers were monitored at the indicated times (day). B, p70s6k activity. BHK21 and tsBN250 cells were transferred to a 39 °C incubator. Cells were harvested at the indicated times, and the activity of p70s6k was measured as described above. The kinase activities of cells before transferring to 39 °C were 12,241 cpm (BHK21) and 29,448 cpm (tsBN250). The data are shown by percentage of activity compared to this value. Results are representative of one of three similar experiments. C, p70s6k and p90rsk activity. tsBN250 cells were transferred to a 39 °C incubator for 30 min with or without supplementation of high concentrations of His (2 mM) or Lys (10 mM). The activity of p70s6k and p90rsk was measured as described above. Results show one representative experiment out of four.


    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Amino acid deprivation inactivated and amino acid supplementation activated p70s6k, indicating that the kinase activity is dependent on amino acid concentration in cell culture media. The activities of other serine/threonine kinases were less affected by amino acid concentration, and moreover, none of these kinases demonstrated the pattern for amino acid dependence that was seen in p70s6k. Amino acid concentration affected phosphorylation of not only p70s6k but also 4E-BP1, which is another translation regulatory molecule controlled by mTOR. Additionally, p70s6k activation and 4E-BP1 phosphorylation induced by amino acid addition was inhibited by rapamycin, a specific inhibitor of mTOR. In contrast, a concentration of wortmannin (100 nM) that almost completely inhibits PI3K activity had only a minor effect on the amino acid-induced p70s6k. mTOR activity is sensitive to only higher concentrations of wortmannin (IC50, ~200 nM), and a partial inhibition of p70s6k by wortmannin (100 nM) may be explained by a partial inhibition of mTOR by the drug. Moreover, amino acid supplementation induced p70s6k in the presence of rapamycin in cells constitutively expressing a rapamycin-resistant mutant of mTOR (S2035I-mTOR). These data indicate that amino acid-dependent regulation of p70s6k requires mTOR but not PI3K. Our data here support the conclusion by Hara et al. (27) that amino acids regulate p70s6k through mTOR itself or an mTOR-controlled downstream element, such as a protein phosphatase. Burnett et al. (19) have recently reported that mTOR has the ability to directly phosphorylate p70s6k at Thr389, which is an essential phosphorylation site for both the activity of p70s6k, and the sensitivity to rapamycin. Furthermore, in yeast, both addition of rapamycin or loss of TOR function (a yeast homolog of mTOR) causes a starvation response in Saccharomyces cerevisiae, suggesting that TOR is a factor to control mRNA translation upon nutrient starvation (40). Additionally, Noda and Ohsumi (41) have recently reported that TOR controls autophagy (a proteolytic response), which is an event also regulated by amino acid concentration. Taken together, mTOR (or TOR in yeast) itself may be regulated by amino acid concentration. In this scenario, an amino acid-sensitive site(s) in mTOR should not reside within its FKBP12/rapamycin binding domain, because amino acids regulated S2035I-mTOR, which does not interact with the FKBP12/rapamycin complex. Because mTOR has a long N-terminal regulatory region (>2,000 amino acids), multiple regulatory mechanisms on mTOR activity would not be unexpected. In the case where the mTOR-controlled downstream element is affected by amino acids, amino acids should regulate this molecule independent of the mTOR-regulatory site because amino acid deprivation decreased S2035I-mTOR-dependent p70s6k activity.

The next question we attempted to answer is how amino acids affect the mTOR/p70s6k pathway. The results obtained using amino acid alcohols, inhibitors of mRNA translation elongation, and temperature-sensitive mutants of tRNA synthetase indicated involvement of tRNA aminoacylation in amino acid-dependent control of p70s6k. All of the inhibitors of neutral amino acid transporters partially suppressed amino acid-induced p70s6k activity, which does not conflict with the idea that intracellular amino acid concentration regulates the pathway through tRNA aminoacylation. Indeed, mechanisms by which unicellular organisms recognize and respond to amino acid starvation is all through the aminoacylation status of tRNA. One aspect of the response to amino acid starvation of Escherichia coli is the accumulation of a regulatory nucleotide, guanosine 3'-diphosphate, 5'-diphosphate (ppGpp), which inhibits several reactions, including transcription of rRNA ("stringent" control). The synthesis of ppGpp is induced by deacylated tRNA (42). Additionally, "attenuation" in amino acid biosynthetic operons is controlled by availability of aminoacyl tRNA (43). The best characterized mechanism by which eukaryotes cope with amino acid starvation is the amino acid-dependent control of yeast GCN2 in S. cerevisiae (44, 45). This serine/threonine kinase has a 530-amino acid sequence related to histidyl-tRNA synthetase at its carboxyl terminus (46). Studies using an RNA binding assay have shown that deacylated tRNA can bind to this domain of GCN2 (47). Upon amino acid starvation, surplus deacylated tRNAs are thought to bind to GCN2 and activate GCN2 protein kinase activity (48). Although the carboxyl terminus of GCN2 has homology to histidyl-tRNA synthetase, it seems that deacylated forms of other tRNAs in addition to histidyl-tRNA can activate GCN2 as well. It seems that there has been sufficient genetic drift in the histidyl-tRNA synthetase domain of GCN2 that it now lacks the ability to discriminate between the binding of different tRNAs (45). mTOR or p70s6k does not have any sequence homology with tRNA synthetases, implying that tRNA may not interact with mTOR or p70s6k directly. Indeed, addition of a yeast tRNA mixture to immunoprecipitated mTOR and p70s6k does not suppress activity of the kinases to phosphorylate 4E-BP1 and S6, respectively, in vitro (data not shown). If amino acid-dependent control of p70s6k is through mTOR, tRNA may interact with an unidentified upstream regulator of mTOR. Withdrawal of most individual amino acids inhibited p70s6k in Chinese hamster ovary cells, although with differing potency (27). In our system, a variety of L-amino acid alcohols was effective to inhibit p70s6k. These data suggest that most deacylated tRNAs would be sufficient to suppress p70s6k with differing potency, as they were demonstrated to activate GCN2 in yeast. One candidate for an upstream regulator of mTOR would be a mammalian homologue of GCN2, although it has not been cloned or identified yet to date. Histidinol was among the most effective amino acid alcohols in the suppression of p70s6k, which may support the idea that the upstream regulatory molecule of mTOR contains a domain homologous to histydyl-tRNA synthetase, as does yeast GCN2.

A rebound of p70s6k activity was detected during deprivation of His or by addition of lower doses of histidinol. Similar results were obtained by deprivation of other individual amino acids or by addition of other amino acid alcohols, although to various extents (data not shown). Additionally, a rebound of p70s6k activity was also observed when tsBN250 cells were transferred to nonpermissible temperature. These effects might be explained by proteolytic responses induced by amino acid deprivation. Because TOR was demonstrated to be involved in autophagic responses in yeast (41), inhibition of mTOR by amino acid deprivation might induce a proteolytic response in mammalian cells, which in turn increases intracellular amino acid concentrations and subsequently reactivates the mTOR/p70s6k pathway.

In contrast to intensive studies on signaling mechanisms regulated by growth factors, our understanding of intracellular signal transduction controlled by nutrients such as amino acids is very limited, especially in mammalian cells. p70s6k (and potentially its upstream kinase mTOR) has been shown to be a protein kinase that is tightly controlled by amino acid concentration. Moreover, the study reported here demonstrates for the first time the involvement of tRNA aminoacylation for the regulation. Our data give us a basis for study directions to reveal an entire signaling mechanism for amino acid-dependent control of mRNA translation (and potentially protein degradation as well) in mammalian cells.

    ACKNOWLEDGEMENTS

We are indebted to Drs. Mike Kilberg (Gainesville, FL), Kozo Takase (Tokyo, Japan), and John Kappler for helpful discussions; Drs. Joe Lucas, John Cambier, and Gary Johnson for critical reading of the manuscript; and Dr. Erwin Gelfand for continuous encouragement of the work.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grants CA-64685 (to N. T.) and CA-23099 (to P. J. H.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel To whom correspondence should be addressed: Dept. of Pediatrics, Div. of Basic Sciences, National Jewish Medical and Research Center, 1400 Jackson St., Denver, CO 80206. Tel.: 303-398-1855; Fax: 303-270-2182; E-mail: teradan{at}njc.org.

The abbreviations used are: s6k, S6 kinase; 4E-BP1, eIF-4E-binding protein 1; PI3K, phosphatidyl inositol-3 kinase; MeAIB, methyl 2-aminoisobutyric acid; eIF, eukaryotic (or eucaryotic) initiation factor; TOR, target of rapamycin; mTOR, mammalian TOR; FCS, fetal calf serum; WT, wild type; ts, temperature-sensitive.
    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Reinhard, C., Thomas, G., and Kozma, S. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4052-4057[Abstract]
  2. Susa, M., Olivier, A. R., Fabbro, D., and Thomas, G. (1989) Cell 57, 817-824[Medline] [Order article via Infotrieve]
  3. Terada, N., Franklin, R. A., Lucas, J. J., Blenis, J., and Gelfand, E. W. (1993) J. Biol. Chem. 268, 12062-12068[Abstract/Free Full Text]
  4. Bandi, H. R., Ferrari, S., Krieg, J., Meyer, H. E., and Thomas, G. (1993) J. Biol. Chem. 268, 4530-4533[Abstract/Free Full Text]
  5. Kawasome, H., Papst, P., Webb, S., Keller, G. M., Johnson, G. L., Gelfand, E. W., and Terada, N. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 5033-5038[Abstract/Free Full Text]
  6. Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., and Thomas, G. (1997) EMBO J. 16, 3693-3704[Abstract/Free Full Text]
  7. von Manteuffel, S. R., Dennis, P. B., Pullen, N., Gingras, A.-C., Sonenberg, N., and Thomas, G. (1997) Mol. Cell. Biol. 17, 5426-5436[Abstract]
  8. Proud, C. G. (1992) Curr. Top. Cell Regul. 32, 243-369[Medline] [Order article via Infotrieve]
  9. Terada, N., Lucas, J. J., Szepesi, A., Franklin, R. A., Takase, K., and Gelfand, E. W. (1992) 186, 1315-1321
  10. Cheatham, B., Vlahos, C. L., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911[Abstract]
  11. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) Nature 370, 71-75[CrossRef][Medline] [Order article via Infotrieve]
  12. Weng, Q.-P., Andrabi, K., Klippel, A., Kozlowski, M. T., Williams, L. T., and Avruch, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5744-5748[Abstract]
  13. Burgering, B. M. T., and Coffer, P. J. (1995) Nature 376, 599-602[CrossRef][Medline] [Order article via Infotrieve]
  14. Alessi, D. R., Kozlowski, M. T., Weng, Q.-P., Morrice, N., and Avruch, J. (1998) Curr. Biol. 8, 69-81[Medline] [Order article via Infotrieve]
  15. Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., and Thomas, G. (1998) Science 279, 707-710[Abstract/Free Full Text]
  16. Abraham, R. T., and Wiederrecht, G. J. (1996) Annu. Rev. Immunol. 14, 483-510[CrossRef][Medline] [Order article via Infotrieve]
  17. Brown, E. J., and Schreiber, S. L. (1996) Cell 86, 517-520[Medline] [Order article via Infotrieve]
  18. Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Shin, T. B., and Schreiber, S. L. (1995) Nature 377, 441-446[CrossRef][Medline] [Order article via Infotrieve]
  19. Burnett, P. E., Barrow, R. K., Cohen, N. A., Snyder, S. H., and Sabatini, D. M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1432-1437[Abstract/Free Full Text]
  20. Lin, T.-A., Kong, X., Saltiel, A. R., Blackshear, P. J., and Lawrence, J. C., Jr. (1995) J. Biol. Chem. 270, 18531-18538[Abstract/Free Full Text]
  21. Beretta, L., Gingras, A.-C., Svitkin, Y. V., Hall, M. N., and Sonenberg, N. (1996) EMBO J. 15, 658-664[Abstract]
  22. von Manteuffel, S. R., Gingras, A.-C., Ming, X.-F., Sonenberg, N., and Thomas, G. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4076-4080[Abstract/Free Full Text]
  23. Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I., and Avruch, J. (1997) J. Biol. Chem. 272, 26457-26463[Abstract/Free Full Text]
  24. Brunn, G. J., Hudson, C. C., Sekulic, A., Williams, J. M., Hosoi, H., Houghton, P. J., Lawrence, J. C., Jr., and Abraham, R. T. (1997) Science 277, 99-101[Abstract/Free Full Text]
  25. Blommaart, E. F. C., Luiken, J. J. F. P., Blommaart, P. J. E., van Woerkom, G. M., and Meijer, A. J. (1995) J. Biol. Chem. 270, 2320-2326[Abstract/Free Full Text]
  26. Fox, H. L., Kimball, S. R., Jefferson, L. S., and Lynch, C. J. (1998) Am. J. Physiol. 274, C206-213[Abstract/Free Full Text]
  27. Hara, K., Yonezawa, K., Weng, Q.-P., Kozlowski, M. T., Belham, C., and Avruch, J. (1998) J. Biol. Chem. 273, 14484-14494[Abstract/Free Full Text]
  28. Douglass, E. C., Valentine, M., Etcubanas, E., Parham, B. L., Weber, P. J., Houghton, P. J., Houghton, J. A., and Green, A. A. (1987) Cytogenet. Cell. Genet. 45, 148-155[Medline] [Order article via Infotrieve]
  29. Kumakura, T., Takase, T., Terada, N., and Gelfand, E. W. (1995) Life Sci. 57, 75-81
  30. Banerjee, P., Ahmad, M. F., Grove, J. R., Kozlosky, C., Price, D. J., and Avruch, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8550-8554[Abstract]
  31. Sugiyama, H., Papst, P., Fujita, M., Gelfand, E. W., and Terada, N. (1997) Oncogene 15, 443-452[CrossRef][Medline] [Order article via Infotrieve]
  32. Christensen, H. N. (1990) Physiol. Rev. 70, 43-77[Free Full Text]
  33. Hansen, B. S., Vaughan, M. H., and Wang, L. (1972) J. Biol. Chem. 247, 3854-3857[Abstract/Free Full Text]
  34. Kilberg, M. S., Hutson, R. G., and Laine, R. O. (1994) FASEB J. 8, 13-19[Abstract/Free Full Text]
  35. Pestka, S. (1971) Annu. Rev. Microbiol. 25, 487-562[CrossRef][Medline] [Order article via Infotrieve]
  36. Thompson, L. H., Lofgren, D. J., and Adair, G. M. (1978) Somat. Cell Genet. 4, 423-435[Medline] [Order article via Infotrieve]
  37. Hamilton, T. A., and Litt, M. (1976) Biochim. Biophys. Acta 435, 362-375[Medline] [Order article via Infotrieve]
  38. Fukushima, K., Motomura, S., Kuraoka, A., Nakano, H., and Nishimoto, T. (1996) Genes Cells. 1, 1087-1099[Abstract/Free Full Text]
  39. Motomura, S., Fukushima, K., Nishitani, H., Nawata, H., and Nishimoto, T. (1996) Genes Cells. 1, 1101-1112[Abstract/Free Full Text]
  40. Barbet, N. C., Schneider, U., Helliwell, S. B., Stansfield, I., Tuite, M. F., and Hall, M. N. (1996) Mol. Biol. Cell 7, 25-42[Abstract]
  41. Noda, T., and Ohsumi, Y. (1998) J. Biol. Chem. 273, 3963-3966[Abstract/Free Full Text]
  42. Haseltine, W. A., and Block, R. (1973) Proc. Natl. Acad. Sci. U. S. A. 70, 1564-1568[Abstract]
  43. Kolter, R., and Yanofsky, C. (1982) Ann. Rev. Genet. 16, 113-134[Medline] [Order article via Infotrieve]
  44. Hinnebusch, A. G. (1988) Microbiol. Rev. 52, 248-273
  45. Wek, R. C. (1994) Trends Biochem. Sci. 19, 491-496[CrossRef][Medline] [Order article via Infotrieve]
  46. Wek, R. C., Jackson, B. M., and Hinnebusch, A. G. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 4579-4583[Abstract]
  47. Wek, S. A., Zhu, S., and Wek, R. C. (1995) Mol. Cell. Biol. 15, 4497-4506[Abstract]
  48. Dever, T. E., Feng, L., Wek, R. C., Cigan, A. M., Donahue, T. F., and Hinnebusch, A. G. (1992) Cell 68, 585-596[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.